Shanghai Skin Disease Hospital, Shanghai Clinical College of Dermatology, Fifth Clinical Medical College, Anhui Medical University, Shanghai 200443, China.
Shanghai Skin Disease Hospital, Institute of Dermatology, School of Medicine, Tongji University, Shanghai 200443, China.
Int Immunopharmacol. 2024 May 10;132:111989. doi: 10.1016/j.intimp.2024.111989. Epub 2024 Apr 8.
Worldwide, tens of thousands of people die from melanoma each year, making it the most frequently fatal form of cutaneous cancer. Immunotherapeutic advancements, particularly with anti-PD-1 medications, have significantly enhanced treatment outcomes over recent decades. With the broad application of anti-PD-1 therapies, insights into the mechanisms of resistance have evolved. Despite the development of combination treatments and early predictive biomarkers, a comprehensive synthesis of these advancements is absent in the current literature. This review underscores the prevailing knowledge of anti-PD-1 resistance mechanisms and underscores the critical role of robust predictive biomarkers in stratifying patients for targeted combinations of anti-PD-1 and other conventional or innovative therapeutic approaches. Additionally, we offer insights that may shape future melanoma treatment strategies.
全世界每年有数万人死于黑色素瘤，使其成为最常见的致命皮肤癌。免疫治疗的进步，特别是抗 PD-1 药物的应用，在最近几十年显著改善了治疗效果。随着抗 PD-1 治疗的广泛应用，对耐药机制的认识也在不断发展。尽管联合治疗和早期预测生物标志物的发展，但目前的文献中缺乏对这些进展的全面综合。本综述强调了抗 PD-1 耐药机制的现有知识，并强调了强大的预测生物标志物在为患者分层以进行抗 PD-1 与其他常规或创新治疗方法的靶向联合治疗方面的关键作用。此外，我们还提供了可能影响未来黑色素瘤治疗策略的见解。
